Post-operative radiotherapy/chemoradiotherapy

RADIATION2 trials

Sponsors

Shanghai Jiao Tong University School of Medicine

Conditions

Induction ChemotherapyInductive TherapyOral CancerProgrammed Cell Death 1 InhibitorVEGFR2 Inhibitor

Phase 1

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

CompletedNCT04393506

Shanghai Jiao Tong University School of MedicineInductive Therapy, Oral Cancer, Programmed Cell Death 1 Inhibitor +1

Start: 2020-04-23End: 2023-11-10Updated: 2023-11-22

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

CompletedNCT04473716

Shanghai Jiao Tong University School of MedicineInduction Chemotherapy, Inductive Therapy, Oral Cancer +1

Start: 2020-07-30End: 2023-09-30Updated: 2023-11-22

Related Papers

De-escalate surgery of primary lesions after neoadjuvant immune-combination therapy in locally advanced oral squamous cell carcinoma: The 5-year survival results of two single-arm trials.

Journal of Clinical Oncology2026-05-28

dNLR and tumor infiltrated neutrophils predict the efficacy of neoadjuvant anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib in locally advanced resectable oral squamous cell carcinoma

International Journal of Surgery2026-05-07

Major pathological response to neoadjuvant immune-related therapy and influence on long-term survival in patients with locally advanced oral squamous cell carcinoma.

Journal of Clinical Oncology2025-05-28

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

Nature Communications2022-09-14110 citations

Neoadjuvant trial with toripalimab, albumin paclitaxel, and cisplatin on pathological response in locally advanced resectable oral squamous cell carcinoma (Illuminate Trial).

Journal of Clinical Oncology2022-06-014 citations

Inductive camrelizumab and apatinib for patients with locally advanced and resectable oral squamous cell carcinoma: A single-arm trial (Icemelting trial).

Journal of Clinical Oncology2021-05-207 citations